Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 ...

26% reduction in risk of death (HR=0.74) and 28% risk reduction in progression or death (HR=0.72) in previously-treated patients administered with CM24+nivolumab+Nal/IRI/5FU/LV vs. standard-of-care(SoC) based on preliminary interim dataProlongation of

Related Keywords

Israel ,Rehovot ,Hamerkaz ,United States ,Spain ,American ,James Heins ,Lior Fhima ,Michael Cecchini ,Gil Efron ,American Society Of Clinical Oncology ,Exchange Commission ,Yale Cancer Center ,Purple Biotech Ltd ,Company Contact ,Bristol Myers Squibb ,Drug Administration ,Purple Biotech ,Clinical Oncology ,Overall Survival ,Chief Executive Officer ,Tumor Associated Antigen ,Looking Statements ,Safe Harbor ,Private Securities Litigation Reform Act ,Annual Report ,Registration Statements ,